## **Pharmacy and Therapeutics Committee Meeting Record**

Date: 09/19/03 Time: 9:00 a.m. – 4:00 p.m. Location: 3380 Americana Terrace, Suite 130 Moderator: Thomas R. Young, M.D.

Committee Members Present: Thomas Young, M.D.; George Pfoertner, M.D.; Catherine Gundlach, PharmD; Jeffery Edwards, M.D.; Rick Sutton, RPh; James Schroeder, P.A.; Bob Comstock, RPh; Thomas Rau, M.D.; Shawna Kittridge, MHS, RPh

Committee Members Absent: Richard Pines, D.O., Richard Markuson, RPh; Steve Montamat, M.D.

Agenda Item	Presenter	Outcome/Action	Assigned	Due
CALL TO ORDER	Thomas R. Young, M.D.			
Roll Call		Dr. Young called the roll and announced that Dr. Pines would not be in attendance.		
Reading of Confidentiality Statement		The confidentiality statement was read by Dr. Young.		
Introduction of Medicaid     Administrator		David Rogers was introduced as the Administrator for the Division of Medicaid. Mr. Rogers gave a brief description of his background and his expectations of the Committee's outcomes.		
Opening Statements		During this meeting, the Committee will be reviewing evidence on two classes of medication. During the October Committee meeting, further information will be presented and the Committee will be asked to make decisions related to these two classes of drugs. It should be noted that this will not be the normal procedure in the future.		
		Dr. Young stated that public comment will be held at the end of the meeting and informed the audience that any scientific information should be given to the evidence-based group prior to the Committee meetings.		
COMMITTEE ADMINISTRATIVE ITEMS	Thomas R. Young, M.D.			
• Approval of Minutes from July 11, 2003, Meeting		The minutes from the July 11, 2003, Committee meeting were approved with no changes.		
Selection of Future Meeting Dates		The next scheduled Committee meeting will be held on October 17. A Committee meeting has also been scheduled for November 21. Following the November 21 meeting, the Committee will meet every other month.		

Agenda Item	Presenter	Outcome/Action	Assigned	Due
Committee Recommendations of Next Drug Classes to Review		A list of existing evidence-based material that has been produced was distributed to Committee members in their packets. This list also contained base utilization data and will be updated in the future. Committee members were asked to assist in determining which class(es) will be reviewed during the January and March meetings. The consensus of the Committee is to review the following:		
		<ul> <li>January – ACE inhibitors and calcium channel blockers</li> <li>March – Opioids and skeletal muscle relaxers</li> <li>May – Urinary incontinence and hypoglycemics (tentative)</li> </ul>		
Committee Recommendations of Next Drug Classes to Request EPC to Review		The Pharmacy Unit has comprised a list of the top 100 classes by expenditure and breaks down what is included in each group. The Committee was asked to identify which therapeutic classes they would like to see evidence gathered on. The Committee was reminded that this recommendation does not mean a recommendation for prior authorization.		
		After some discussion, the Committee determined they would like to see the evidence-based group review and have evidence gathered on the following:		
		<ul> <li>Antidepressants, specifically the SSRIs</li> <li>Psychotherapeutic Agents and Others, including stimulants and other ADHD medications</li> <li>Newer Atypicals</li> </ul>		
		<ul> <li>Mood Stabilizers</li> <li>Beta 2 Agonists</li> <li>Inhaled Steroids</li> <li>ARBs</li> </ul>		
		ACTION: Dr. Young will develop questions regarding information the Committee would specifically like to see. These questions will be presented to the evidence-based group for a determination on whether this information could be gathered. These questions will be reviewed by Committee members prior to sending them to the evidence-based group.	Dr. Young	10/17/03

Agenda Item	Presenter	Outcome/Action	Assigned	Due
DRUG CLASS REVIEW	Tami Eide, Pharm.D., BCPS, FASHP			
• PPI		Tami presented slides explaining the review of PPIs,		
		including how the drugs work, the drug-drug interaction, and the Medicaid prior authorization guidelines. This review		
		included the following drugs:		
		<ul><li>Esomeprazole</li><li>Lansoprazole</li></ul>		
		Cansoprazole     Omeprazole		
		Pantoprazole		
		Rareprazole		
REVIEW OF CLINICAL DATA	Roger Chou, M.D.			
• PPI		Dr. Chou presented slides explaining the clinical data for PPI		
		medications. This information was also provided to		
		Committee members in their meeting packets as well. Dr. Chou explained the search strategy, data collection and		
		analysis, the inclusion criteria for the PPI results and		
		outcomes. The key questions they looked for include:		
		Comparative efficacy, comparative safety and subpopulations.		
		Dr. Chou also discussed the findings for healing of		
		esophagitis or relief from GERD symptoms, healing or		
		symptom relief of duodenal ulcer, healing or symptom relief of gastric ulcer, healing or symptom relief or prevention of		
		NSAID-induced ulcer, and helicobacter pylori eradication.		
		Evidence of adverse events was explained as well as the		
		differences in efficacy or safety based on a subgroup and		
		possible theoretical concerns that have been identified.		
		ACTION: These medications are not recommended for	Dr. Chou	10/17/03
		pediatric use but it is unclear if this is due to the method of delivery. Dr. Chou will follow up with his colleagues		
		regarding pediatric use. Dr. Chou will also follow up on		
		any clinical data as it relates to food interactions and the		
DDIIC CLASS DEVIEW	Tomi Eido Dharra D. DCDC	formulations.		
DRUG CLASS REVIEW	Tami Eide, Pharm.D., BCPS, FASHP			
• COX2		Tami explained how the nonsteroidal anti-inflammatory		
		agents work, the Cyclooxygenase pathways, the		
		pharmacokinetics, the serious adverse effects, allergy		

Agenda Item	Presenter	Outcome/Action	Assigned	Due
		contraindications, drug interactions, and the current Medicaid prior authorization criteria for approval. Current COX2 medications reviewed include:		
		<ul><li>Celecoxib</li><li>Rofecoxib</li><li>Valdecoxib</li></ul>		
REVIEW OF CLINICAL DATA	Roger Chou, M.D.	v didecomo		
• COX2		Dr. Chou present slides explaining the clinical data for COX-2 medications. Inclusion criteria included populations with osteoarthritis, rheumatoid arthritis, soft tissue pain, and back pain. The clinical data reviewed were three Coxibs and COX-2 selective NSAIDS. Dr. Chou explained the outcomes and the serious adverse events and the results of the efficacy and safety study. It was determined that the dropout rates for the study were less than ten percent at six weeks.  The study's conclusion is that there is no difference in efficacy across comparisons and no significant findings in subgroups (age, sex, race/ethnicity).		
		ACTION: Committee members would like to see utilization rates based on age when the utilization data is reviewed at the next meeting. Committee members would also like outcomes from other states and most common	Pharmacy Unit	10/17/03
		dose utilization. Tami will provide the reports from the three studies to the Committee members. If Committee members would like further information, they can email Neil and that information will be past on.	Tami	10/17/03
PUBLIC COMMENT FOR CURRENT THERAPEUTIC CLASSES UNDER REVIEW	Thomas R. Young, M.D.	Public comment guidelines were reviewed with those in attendance. Public comment was received from the following:		
		<ul> <li>David Beeman, Astra Zeneca – PPI's</li> <li>Mark Shigihara, Wyeth – PPI's</li> <li>Jillmarie Yanchick, Pfizer – Nsaids</li> <li>Daryl MacCarter, M.D. – Nsaids</li> <li>Robert Popoula, Pfizer – Nsaids</li> <li>Dan Heinsi, Merck – Nsaids</li> </ul>		
ADJOURN COMMITTEE MEETING	Thomas R. Young, M.D.	The meeting was adjourned and the next meeting will be held on Friday, October 17, 2003.		

Agenda Item Presenter	Outcome/Action	Assigned	Due	1
-----------------------	----------------	----------	-----	---